News Eisai: UK gives pharma a poor deal, may invest elsewhere Japanese pharma getting frustrated with NICE
News NICE rejects Eisai's Halaven in new breast cancer use NICE rejects drug after finding gap in clinical data
News NICE rejects Bayer and Eisai drugs in thyroid cancer Thyroid cancer drugs are available in Scotland and Wales
Views & Analysis Medical Affairs – the heart of a data-driven, patient-centri... Kirk Shepard, Eisai’s SVP of Global Medical Affairs Oncology, talks about how his profession has developed hugely in recent years, and how the new Medical Affairs Professional Society (MAPS) wi
News NICE finally recommends Eisai breast cancer drug after rethi... New trial evidence and price cut convinces NICE in reassessment.
News Nissan stays in UK - but will Japanese pharma? Japanese R&D investment could follow EMA out of UK - experts.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.